Apitoxin is a chemically defined substance encountered in pharmaceutical manufacturing whose health-based exposure limit derivation requires integration of pharmacological, toxicokinetic, and general toxicological data to identify the most relevant point of departure. The quality and completeness of the toxicological database for Apitoxin directly influences the magnitude of uncertainty factors applied and the confidence in the resulting PDE value. Periodic review of new published data and post-market clinical safety signals ensures that the OEL for Apitoxin remains protective as scientific knowledge develops.
Interspecies uncertainty factor F1 refinement for Apitoxin is achievable when comparative toxicokinetic data characterise the AUC ratio between humans and the test species at relevant doses, replacing the default allometric scaling assumption.
